# Younger, Lighter, Drier: The Impact of Age and Body Mass Index on Treatment Success in Pediatric Monosymptomatic Nocturnal Enuresis

**Authors:** Gokhan Demirtas, Gunay Ekberli, Suleyman Tagci, Huseyin Tugrul Tiryaki

PMC · DOI: 10.3390/children13020241 · Children · 2026-02-09

## TL;DR

Younger children and those with lower BMI are more likely to successfully treat bedwetting, suggesting treatment plans should consider age and weight.

## Contribution

This study identifies age and BMI as independent predictors of treatment success in pediatric nocturnal enuresis.

## Key findings

- Younger age is linked to higher treatment success rates in bedwetting.
- Lower BMI correlates with better early treatment response and shorter treatment duration.
- Overweight children require longer treatment and show reduced response rates.

## Abstract

What are the main findings?
Younger age and lower body mass index are independently associated with higher treatment success in pediatric monosymptomatic nocturnal enuresis.Overweight and older children show significantly reduced response rates to standard first-line therapies.

Younger age and lower body mass index are independently associated with higher treatment success in pediatric monosymptomatic nocturnal enuresis.

Overweight and older children show significantly reduced response rates to standard first-line therapies.

What are the implications of the main findings?
Age and body mass index should be considered when counseling families and setting realistic expectations for treatment outcomes.Early intervention and weight-aware management strategies may improve therapeutic success in pediatric nocturnal enuresis.

Age and body mass index should be considered when counseling families and setting realistic expectations for treatment outcomes.

Early intervention and weight-aware management strategies may improve therapeutic success in pediatric nocturnal enuresis.

Objectives: To evaluate the effects of age, body mass index, and treatment duration on treatment response in children with primary monosymptomatic nocturnal enuresis and to determine the contribution of these variables to clinical outcomes. Methods: Data from 560 pediatric patients treated with desmopressin due to primary monosymptomatic nocturnal enuresis were retrospectively analyzed. Patient demographics, body mass index classifications, early treatment response, and dryness rates at 3 and 6 months were evaluated. Categorical variables were analyzed using the chi-square or Fisher’s exact test, and continuous variables were evaluated using Spearman correlation analysis. Significant factors predicting treatment success were investigated using multivariable analyses. Results: Treatment success was significantly higher in younger age groups, with increased early response rates and shorter treatment duration (p < 0.001). Higher body mass index was associated with a delay in early treatment response and the need for longer treatment (p < 0.0001). While the likelihood of treatment success decreased with increasing age, higher body mass index demonstrated a modest positive association with treatment response after multivariable adjustment. Conclusions: The findings indicate that age and body mass index are important determinants of treatment response in pediatric monosymptomatic nocturnal enuresis. These results suggest that treatment strategies should be individualized by considering both age and body mass index.

## Linked entities

- **Chemicals:** desmopressin (PubChem CID 5311065)
- **Diseases:** nocturnal enuresis (MONDO:0000022)

## Full-text entities

- **Diseases:** injury to (MESH:D014947), polyuria (MESH:D011141), detrusor overactivity (MESH:D053201), antidiuretic hormone (MESH:D007177), Overweight (MESH:D050177), Obesity (MESH:D009765), lower (MESH:D017116), urine loss (MESH:D014555), enuresis (MESH:D004775), enuretic symptoms (MESH:D012816), Nocturnal Enuresis (MESH:D053206), Dryness (MESH:D014987), urinary tract disorders (MESH:D014570), sleep-disordered breathing (MESH:D012891)
- **Chemicals:** enuretic (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12939050/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12939050/full.md

---
Source: https://tomesphere.com/paper/PMC12939050